Emrah KESKİN, Özlem ELMAS, Hasan Ali AYDIN, Kenan Şimşek, Eren Görkem GÜN, Murat KALAYCI

Glioblastome Multiforme Epidemiyolojisi, Tedavi Seçenekleri ve Sağkalım Süresi: Retrospektif Tek Merkezli Çalışma

Amaç: Glioblastoma multiforme (GBM), primer beyin tümörlerinin en sık görülenidir. Tedavisi ile ilgili çok sayıda klinik ve deneysel çalışma yapılmasına rağmen; GBM’in tedavi seçenekleri çok fazla değişmemiştir. Çalışmamız, GBM’li hastaların epidemiyolojisi, tedavi seçenekleri ve sağkalım süreleri arasındaki ilişkiyi incelemek amacıyla planlandı. Gereç ve Yöntemler: Bu çalışmada, 2017-2019 yılları arasında Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Beyin ve Sinir Cerrahisi Anabilim Dalı’nda GBM tanısı alan 72 hasta retrospektif olarak değerlendirilmiştir. Bu hastaların tedavi modaliteleri, epidemiyolojileri ve sağkalım süreleri incelenmiştir. Bulgular: Hastaların 28’i kadın, 44’ü erkek olup, %55,6’sı 60 yaş üstüdür. Cinsiyet ile sağkalım süresi arasındaki fark istatistiksel olarak anlamlı değildir (p=0,303>0,05). Yaş arttıkça sağkalım süresinde %28,9 oranında azalış olduğu görülmüştür. GBM lokalizasyon olarak en sık temporopariyatel yerleşimli olduğu gözlenirken, tümör lokalizasyonu ile sağkalım süresi arasında anlamlı fark görülmedi. Sonuç: Çalışmamızın sonucunda GBM’li hastalarda, yaşın ve kombine tedavi seçeneğinin önemli bir prognostik faktörler olduğu görülmüştür.

Epidemiology, Treatment Options and Survival Analysis in Glioblastoma Multiforme: A Retrospective Single Center Study

Aim: Glioblastoma multiforme (GBM) is the most common of primary brain tumors. Although there are many clinical and experimental studies about its treatment; options for treatment of GBM have not changed much. Our study was planned to examine the relationship between epidemiologies, treatment options and survival times of patients with GBM. Material and Methods:In this study, 72 patients diagnosed with GBM between 2017-2019 in Zonguldak Bülent Ecevit University Faculty of Medicine Department of Brain and Neurosurgery were evaluated retrospectively. These patients’ treatment modalities, epidemiologies and survival times were examined. Results: 28 of the patients are female, 44 of them are male, 55.6% of them are over the age of 60. The difference in survival. The relationship between gender and survival time is not revealing (p=0.303>0.05) It was observed that the survival time decreased by 28.9% with increasing age. While GBM was observed most frequently temporoparietal settlement as localization, there was no significant difference between tumor localization and survival time. Conclusion: As a result of our study, it was observed that age and combined treatment options are important prognostic factors in patients with GBM.

PDF

___

1. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane, Australia: Codon Publications; 2017. https://doi.org/10.15586/codon.glioblastoma.2017.ch8.
2. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2012;19(4):764-772.
3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131(6):803-820.
4. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz- Sloan JS. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro-Oncology 2020;22(Supplement_1):1-96.
5. Altinoz MA, Nalbantoglu J, Ozpinar A, Ozcan ME, Del Maestro RF, Elmaci I. From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo. Clin Neurol Neurosurg 2018;173:20-30.
6. Shahcheraghi SH, Zangui M, Lotfi M, Ghayour-Mobarhan M, Ghorbani A, Jaliani HZ, Sadeghnia HR, Sahebkar A. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr Pharm Des 2019;25(3):333-342.
7. Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X. Advances in immunotherapy for glioblastoma multiforme. J Immunol Res 2017;1-11.
8. Von Neubeck C, Seidlitz A, Kitzler HH, Beuthien-Baumann B, Krause M. Glioblastoma multiforme: Emerging treatments and stratification markers beyond new drugs. Br J Radiol 2015;88(1053):20150354.
9. Hamisch C, Ruge M, Kellermann S, Kohl AC, Duval I, Goldbrunner R, Grau SJ. Impact of treatment on survival of patients with secondary glioblastoma. JJ Neurooncol 2017;133(2):309-313.
10. Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N. Association of surgical resection, disability, and survival in patients with glioblastoma. J Neurol Surg A Cent Eur Neurosurg 2019;80(04):262-268.
11. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003;145(1):5-10.
12. Salgado MV, Torres J, Esteban J, Gutiérrez JA, Ley L, Carrato A. Survey of treatment recommendations for elderly patients with glioblastoma. Clin Transl Oncol 2020;22:1329-1334.
13. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-764.
14. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996.
15. Carlsson SK, Brothers SP, Wahlestedt D. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 2014;6(11):1359-1370.
16. Ampie L, Woolf EC, Dardis C. Immunotherapeutic advancements for glioblastoma. Front Oncol 2015;5:12.
17. Batash R, Asna N, Schaffer P, Francis N, Schaffer M (2017). Glioblastoma multiforme, diagnosis and treatment; Recent literature review. Curr Med Chem 2017;24(27):3002-3009.
18. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008;31:300-305.
19. Malmström A, Grøonberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R. Nordic Cinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012;13(9):916-926.
20. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches. Radiat Oncol Lond Engl 2011;6:2.
21. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez Tiedra S, Salazar M, Garcia-Taboada E, Barcia J, Guzman M, Velasco G. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10(Suppl. 1):90-103.
22. Mantwill K, Naumann U, Seznec J, Girbinger V, Lage H, Surowiak P, Beier D, Mittelbronn M, Schlegel J, Holm PS. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Trans Med 2013;11:216.
23. Hoffmann D, Wildne, O. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther 2007;14(7):627- 639.
24. Stupp R, Wong E, Scott C, Taillibert S, Kanner A, Kesari S, Ram Z, on behalf of the EF. NT-40Interim analysis of the EF-14 Trial: A prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly Diagnosed GBM. Neuro-Oncology 2014;16:v167.
25. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta neurochirurgica. 2003;145(1):5-10.
26. Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S. Survival and prognostic factors for glioblastoma multiforme: Retrospective single-institutional study. Indian J Cancer 2017;54(1):362.
27. Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M. Association of the extent of resection with survival in glioblastoma: A Systematic review and meta-analysis. JAMA Oncol 2016;2:1460-1469.
28. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor, G, Delattre JY. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356(15):1527-1535.
29. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New N Engl J Med 2005;352(10):987-996.
30. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-466.
31. Simińska D, Korbecki J, Kojder K, Kapczuk P, Fabiańska M, Gutowska I, Machoy-Mokrzyńska A, Chlubek D, Baranowska- Bosiacka I. Epidemiology of Anthropometric Factors in Glioblastoma Multiforme—Literature Review. Brain Sci 2021;11(1):116.
32. Tian M, Ma W, Chen Y, Yu Y, Zhu D, Shi J, Zhang Y. Impact of gender on the survival of patients with glioblastoma. Biosci Rep 2018;38(6):BSR20180752.
33. Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, Bergsneider M, Nghiemphu PL, Lai A, Liau LM, Cloughesy TF, Yong WH. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. J Neurooncol 2017;132(2):351-358.
34. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P. Genetic pathways to glioblastoma: A population- based study. Cancer Res 2004;64(19):6892-6899.
35. Li K, Lu D, Guo Y, Wang C, Liu X, Liu Y, Liu D. Trends and patterns of diffuse glioma in the United States, 1973-2014. Cancer Med 2018;7:5281-5290.